Abstracts

Effective Exposure to Atazanavir During Pregnancy Regardless of Tenofovir Use

Background: Atazanavir with low-dose ritonavir boosting moved from an alternative protease inhibitor to a preferred protease inhibitor for use in antiretroviral-naive pregnant women. The package insert recommends an atazanavir (ATV) dose increase in the 2nd and 3rd trimester of pregnancy if tenofovir (TDF) or an H2 receptor antagonist is used concomitantly. Conflicting data exist about…

Low Darunavir Exposure During Pregnancy With 800/100mg Darunavir/r QD Dosing

Background: Perinatal guidelines include ritonavir-boosted darunavir (DRV/r) as an alternative protease inhibitor for use in antiretroviral (ARV)-naïve pregnant women. The dosing recommendation for ARV-naive patients is DRV/r 800/100mg QD but pharmacokinetic data on this dose in pregnant women are limited. Methodology: Patients treated with DRV/r (800/100mg QD) during pregnancy had intensive steady-state 24-hour PK profiles…

Pharmacogenetics of Efavirenz Excretion Into Human Breast Milk and Transfer to Breastfed Infants

Background: The influence of drug metabolizing enzyme, transporter and nuclear receptor single nucleotide polymorphisms (SNPs) on efavirenz (EFV) concentrations in human breast milk and infants exposed through breast milk is understudied. SNPs in maternal CYP2B6, NR1I3, ABCG2 and ABCB5 were investigated here. Methodology: HIV positive nursing mothers (n = 51) receiving once daily regimens containing…

Simplification of PI+RTV+FTC/TDF to E/C/F/TDF Maintains HIV Suppression and is Well-Tolerated

Background: Antiretroviral (ARV) regimen simplification can improve treatment adherence and quality of life. We report the Week (W) 48 results of a prospective, randomized, open-label, ongoing Phase 3b trial of a regimen simplification to the single-tablet regimen elvitegravir/cobicistat/emtricitabine/ tenofovir DF (E/C/F/TDF) from ritonavir-boosted protease inhibitor (PI+RTV) plus emtricitabine/tenofovir DF (FTC/TDF) regimens. Methodology: Virologically suppressed subjects…

Paradoxical impact of maraviroc/raltegravir added to HAART in Acute HIV infection: ANRS 147 trial

Background: Early HAART in acute HIV infection (PHI) is recommended at this period of generalized activation, the addition of maraviroc to boost CD4 increase and raltegravir for his potent antiviral effect should reduce HIV reservoirs and immune damage. The randomized multicenter OPTIPRIM-ANRS-147 trial was designed to evaluate the impact of an early 24-month treatment on…

Switch from NNRTI plus FTC/TDF to E/C/F/TDF Maintains HIV Suppression and is Well- Tolerated

Background: Concerns with current and/or long-term side effects or dosing complexity of antiretroviral (ARV) regimen may prompt patients to request ARV switches. We report the Week (W) 48 results of a prospective, randomized, open-label, ongoing Phase 3b trial of a regimen switch to the single-tablet regimen (STR) elvitegravir/cobicistat/emtricitabine/tenofovir DF (E/C/F/TDF) from non-nucleoside reverse transcriptase inhibitor…

Randomised Controlled Trial of a PI Monotherapy Switch Strategy for Long-term HIV Management

Background: Previous randomised trials show patients switching to PI monotherapy maintain high rates of viral load (VL) suppression over 48-96 weeks, sometimes meeting VL non-inferiority criteria. However, longer-term resistance and toxicity risks are uncertain and the place of PI monotherapy in longterm management therefore remains controversial. Methodology: The Protease Inhibitor Versus Ongoing Triple-therapy (PIVOT) trial…

EFFECT OF SELENIUM SUPPLEMENTATION ON CD4 DEPLETION IN RWANDAN HIV PATIENTS: A RANDOMIZED TRIAL

Background: Micronutrient deficiencies occur early in human immunodeficiency virus (HIV) infection and are associated with accelerated disease progression. We aimed to determine if long-term selenium supplementation is effective and safe in delaying CD4 T-cell decline and disease progression when implemented early in adults infected with HIV who are antiretroviral therapy (ART) naive in Rwanda. Methodology:…